1c3

AKR1C3-IN-4, a potent and selective inhibitor of aldo-keto reductase 1C3 (AKR1C3) with an IC50 of 0.56 μM, shows potential for castrate-resistant prostate cancer (CRPC) research.

AKR1C3-IN-1 is a potent and selective inhibitor of AKR1C3(IC50 of 13 nM).

AKR1C3-IN-9, a selective Aldo-keto Reductase 1C3 (AKR1C3) inhibitor (IC50 = 8.92 nM), can significantly reverse Doxorubicin (DOX) resistance in a resistant breast cancer cell line.

AKR1C3-IN-11 (Compound 6e) is an inhibitor of aldehyde ketone reductase 1C3 (AKR1C3) with an IC50 of 2.0 μM. When combined with abiraterone, AKR1C3-IN-11 can suppress cell proliferation and is applicable in prostate cancer research.

AKR1C3-IN-12 (compound 2j), an inhibitor of aldo-keto reductase 1C3 (AKR1C3), exhibits potent activity with an IC50 of 27 nM. It has been shown to enhance the effectiveness of Gemcitabine and Cisplatin in treating bladder cancer [1].

AKR1C3-IN-15 (compound 30) is an effective and selective AKR1C3 inhibitor with an IC50 value of 5 nM. It enhances Sorafenib-induced ROS production, promotes apoptosis, and restores sensitivity to Sorafenib in hepatocellular carcinoma (HCC) models, as demonstrated in both in vitro and in vivo studies.

PROTACAKR1C3 degrader-1 (compound 5) is an efficient AKR1C3 PROTAC degrader. It effectively reduces the protein expression of AKR1C3, AKR1C1/2, and ARv7. PROTACAKR1C3 degrader-1 shows potential for research in prostate cancer.

AKR1C3-IN-13 (Compound 4) is an inhibitor of AKR1C3. It can degrade AKR1C3 within prostate cancer cells.

AKR1C3-IN-6 (Compound 1) is a potent and specific AKR1C3 inhibitor, exhibiting IC50 values of 0.31 μM against AKR1C3 and 73.23 μM against AKR1C2. It demonstrates significant antitumor activity [1].

AKR1C3-IN-7 (Compound 13) is a potent and selective AKR1C3 inhibitor with an IC50 of 0.19 μM, exhibiting antitumor activity.

AKR1C3-IN-8 (Compound 5) is a potent and selective AKR1C3 inhibitor (IC50 = 0.069 μM) with demonstrated antitumor activity.

AKR1C3-IN-5 (Compound 6e) is a potent inhibitor of AKR1C3, derived from drupanin, with significant activity against MCF-7 cells (IC50: 9.6 ± 3 μM; SI: 5.5). AKR1C3 enzymes are overexpressed in hormone-dependent prostate and breast tumors.

AKR1C3-IN-10 (compound 5r), a selective inhibitor of AKR1C3 with an IC50 of 51 nM, demonstrates efficacy in a prostate cancer xenograft model [1].

AKR1C3-IN-14 (compound 4) is an inhibitor of AKR1C3 enzyme, exhibiting an IC50 value of 0.122 μM. It reduces excess androgen production by inhibiting the activity of the AKR1C3 enzyme, thereby regulating hormone-mediated signaling. Additionally, AKR1C3-IN-14 plays a role in the biosynthesis of prostaglandin PGF2α, influencing this pathway to regulate cell proliferation. This compound is utilized in the research of prostate cancer.

Liquiritin (Liquiritigenin-4'-O-glucoside) (LIQ) is a main component among the licorice flavonoids, and possesses anti-inflammatory and anti-cancer abilities.

S19-1035 is a potent and specific inhibitor of aldo-keto reductase 1C3 (AKR1C3), displaying an inhibitory concentration (IC50) of 3.04 nM. It is primarily utilized in tumor research.

S07-2010 is an AKR1C3 inhibitor with potential anti-cancer activity, suppressing AKR1C3, AKR1C4, AKR1C1, and AKR1C2, inducing apoptosis in A549/DDP cells. S07-2010 exhibits significant cytotoxicity in MCF-7/DOX and A549/DDP.

AKR1C1-IN-1 is a human 20α-hydroxysteroid dehydrogenase (AKR1C1) inhibitor (Ki: 4 nM for AKR1C1).

Obafistat is a potent inhibitor of aldo-keto reductase AKR1C3 with an IC50 of 1.2 nM for human AKR1C3.

ASP-9521 is a selective, potent and orally active indole-based AKR1C3 inhibitor with an IC50 of 11 nM for human AKR1C3.

1-b-D-(3-Methoxy naphthalen-2-yl)-2'-deoxyriboside; 1,4-Anhydro-2-deoxy-1-C-(3-methoxy)-naphthalenyl)-D-erythro-pentitol is a useful organic compound for research related to life sciences. The catalog number is TNU1641 and the CAS number is 1117893-19-2.

1-alpha-D-(3-Meth oxynaphthalen-2-yl)-2'-deoxy riboside; (1S)-1,4-Anhy dro-2-deoxy-1-C-(3-methoxy)-naphthalenyl)-D-erythro-pentitol is a useful organic compound for research related to life sciences. The catalog number is TNU1648 and the CAS number is 1502811-53-1.

Odafosfamide ((S)-OBI-3424) is a highly selective prodrug bi-alkylating agent activated by aldo-keto reductase 1C3 (AKR1C3). It exhibits potent cytotoxicity in cell lines with high AKR1C3 expression. Odafosfamide demonstrates antitumor activity in various tumors with elevated AKR1C3 expression, such as liver cancer, non-small cell lung cancer, and leukemia. It is applicable for cancer research.

SN34037 is a specific Aldo-keto reductase 1C3 (AKR1C3) inhibitor capable of reducing PR-104A to PR-104H and inhibiting the cytotoxic activity of PR-104A, suitable for studying PR-104A-responsive leukaemia.